Table 2.

Subgroup analysis for cardiac mortality: Nicorandil use

Factor	Subgroup	n	HR	95% Cl	P value	Interaction P value
Total		334	0.512	0.275–0.953	0.035	-
Age	≥75	143	0.807	0.344–1.890	0.621	0.252
	<75	191	0.380	0.153–0.942	0.037
Sex	Male	255	0.449	0.216–0.932	0.032	0.403
	Female	79	0.737	0.213–2.547	0.629
LVEF	Reduced	244	0.623	0.325–1.192	0.153	0.405
	Preserved	90	0.245	0.029–2.102	0.200
LMT	Present	19	1.240	0.000–3.420	0.581	0.968
	Absent	315	0.492	0.259–0.934	0.030
3VD	Present	85	0.672	0.244–1.849	0.441	0.482
	Absent	249	0.425	0.188–0.962	0.040
PCI	Present	245	0.556	0.272–1.138	0.108	0.646
	Absent	89	0.422	0.120–1.483	0.179
CABG	Present	69	0.181	0.036–0.897	0.036	0.128
	Absent	265	0.718	0.366–1.409	0.336
Diabetes	Present	207	0.412	0.177–0.957	0.039	0.361
	Absent	127	0.742	0.296–1.858	0.523
CKD	Present	229	0.434	0.217–0.871	0.019	0.206
	Absent	105	1.252	0.280–5.596	0.769
Dialysis	Present	44	0.338	0.073–1.568	0.166	0.595
	Absent	290	0.557	0.282–1.100	0.092
β-blockers	Present	278	0.483	0.229–1.022	0.057	0.469
	Absent	56	0.830	0.273–2.523	0.743
Statins	Present	220	0.720	0.324–1.604	0.422	0.425
	Absent	114	0.400	0.139–1.153	0.090
Anti-platelet agents	Present	299	0.600	0.316–1.140	0.119	0.907
	Absent	35	0.041	0.000–215.058	0.464
Nitrates	Present	78	0.551	0.188–1.616	0.277	0.814
	Absent	256	0.474	0.219–1.027	0.058

LVEF left ventricular ejection fraction, LMT left main trunk, 3VD three-vessel disease, PCI percutaneous coronary intervention, CABG coronary artery bypass graft, CKD chronic kidney disease